Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    cesto
Previous Study | Return to List | Next Study

Safety and Efficacity of NFL101 as Tobacco Therapy (CESTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02521701
Recruitment Status : Completed
First Posted : August 13, 2015
Last Update Posted : August 14, 2017
Sponsor:
Information provided by (Responsible Party):
Institut du Cancer de Montpellier - Val d'Aurelle

Brief Summary:
This Phase I study is to investigate the safety of two dose levels of NFL-101 in smokers.

Condition or disease Intervention/treatment Phase
Smoking Drug: NFL101 Phase 1

Detailed Description:

Tobacco addiction is one of the biggest public health threats the world has ever faced, killing nearly six million people a year. There are more than 1 billion smokers in the world, up to half will eventually die of a tobacco-related disease. Nicotine replacement treatments were the first pharmacological treatments approved for use in smoking cessation therapy and include nicotine gums, transdermal patches, tablets, nasal sprays, and inhalation systems. More recently, buproprion and varenicline were approved but showed limiting side effects. The development of safe and efficient alternatives for this indication is now called for.

Tobacco cessation cases were observed concomitantly with the administration of a desensitization treatment against tobacco allergy. Based on these observations, NFL Biosciences developed a drug candidate for tobacco cessation. This new drug (NFL 101) was assessed in preclinical studies. Notably, regulatory genotoxicity (Institut Pasteur de Lille) and toxicity studies in rats (Ricerca, Wil Research, Lyon) showed no toxicity. The NFL 101 composition and the low doses injected led to propose a mechanism of action based on an immune response. Immunogenicity studies conducted with the European Georges Pompidou Hospital (HEGP) on peripheral blood mononuclear cells and rodents have supported such hypotheses. Therefore, the objective of this Phase I study is to investigate the safety of two dose levels of NFL-101 in smokers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study Assessing Safety and Efficacity of NFL101 as Tobacco Therapy(CESTO)
Actual Study Start Date : December 2014
Actual Primary Completion Date : December 2015
Actual Study Completion Date : August 2016

Arm Intervention/treatment
Experimental: NFL101

Level 1: 100 µg

  • 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29
  • The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.

Level 2: 200 µg

  • 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29
  • The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.
Drug: NFL101

Level 1: 100 µg

  • 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29
  • The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.

Level 2: 200 µg

  • 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29
  • The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.




Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of safety in smoking subjects. [ Time Frame: 1 year ]
    to access safety of NFL 101


Secondary Outcome Measures :
  1. to determine immunogenicity of NFL 101 [ Time Frame: 1 year ]
    Response rate as a mesure of efficacy of NFL 101 in smoking subjects.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female subjects ≥ 18 and ≤ 70 years old
  • ECOG/OMS performance status 0-1
  • Subjects currently smoking at least 11 cigarettes per day and with a dependency level ≥ 5 according to Fagerstöm scoring
  • Subjects willing to quit smoking
  • Good general health (i.e. no uncontrolled medical condition)
  • Good mental health (i.e. no alcohol or drug abuse in the past year, no psychiatric history- adequately treated depression is accepted).
  • For women of childbearing age: adequate contraception at least until 28 days after the second injection
  • French speaking
  • Patients must be affiliated to a social security system
  • Informed consent agreement and signature

Exclusion Criteria:

  • Pregnancy and breastfeeding
  • Concomitant participation to another clinical trial
  • Concomitant active infectious diseases
  • Concomitant desensitization therapy
  • History of asthma or immune disorders
  • History of any allergy including to nicotine or any components of study product
  • Uncontrolled diabetes
  • Use of corticosteroids, systemic steroids, antihistamines or immunosuppressive agents within 30 days prior to the study start
  • Prior exposure to a nicotine vaccine or to any other vaccine within 30 days before study product administration
  • Use of any therapy of smoking cessation within 90 days (including use of electronic cigarettes and alternative methods such as hypnosis or acupuncture)
  • Legal incapacity or physical, psychological or mental status interfering with the subject's ability to sign the informed consent or to terminate the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02521701


Locations
Layout table for location information
France
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, France, 34298
Sponsors and Collaborators
Institut du Cancer de Montpellier - Val d'Aurelle
Investigators
Layout table for investigator information
Principal Investigator: Anne STOEBNER ICM
Layout table for additonal information
Responsible Party: Institut du Cancer de Montpellier - Val d'Aurelle
ClinicalTrials.gov Identifier: NCT02521701    
Other Study ID Numbers: ICM2014/34
First Posted: August 13, 2015    Key Record Dates
Last Update Posted: August 14, 2017
Last Verified: August 2017